Lv2
160 积分 2025-11-13 加入
Effects of a Novel Dual Phosphodiesterase 3 and 4 Inhibitor TQC3721 in Patients with COPD in China (PACER-II): a phase 2, multicentre, randomised, double-blind, placebo-controlled trial
5天前
已完结
Effects of a Novel Dual Phosphodiesterase 3 and 4 Inhibitor TQC3721 in Patients with COPD in China (PACER-II): a phase 2, multicentre, randomised, double-blind, placebo-controlled trial
5天前
已关闭
Medical Affairs’ Fundamentals: The Next Generation
20天前
已关闭
Medical Affairs
20天前
已关闭
B cells drive CCR5+CD4+ tissue-resident memory T-cell cytotoxicity via IL-15Rα-IL-15 signaling in primary biliary cholangitis
1个月前
已完结
Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial
1个月前
已完结
Vitiligo: advances in pathophysiology research and treatment development
1个月前
已完结
IL-33, inflammation and mucus in COPD: the final FRONTIER?
2个月前
已完结
New Kids on the Block: IL-23 Inhibitors in IBD Management
2个月前
已完结
皖公网安备34019202002308
